PositiveID Will Offer Its Firefly Dx System Under the SenseNet Program for Faster, Less Expensive Bio-Threat Detection
DELRAY BEACH, Fla., Oct. 10, 2014 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it, in conjunction with its partner, ENSCO, Inc., has been awarded a SenseNet Program contract from the U.S. Department of the Interior on behalf of the U.S. Department of Homeland Security Science & Technology Directorate. The goal of this SenseNet award is to implement faster, less expensive bio-threat detection systems, using existing infrastructure where possible, to provide an added level of security.
As part of this award, PositiveID will offer its Firefly Dx system, which is a point-of-need system designed to deliver molecular diagnostic results using real-time PCR (polymerase chain reaction) chemistry. Firefly is designed to derive results from a sample in less than 20 minutes at the point of sampling, compared to two to four hours for a lab device, which would enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems, helping to save lives. ENSCO will be responsible for the systems integration and decision support.
“We are pleased to work with ENSCO on this effort for the Department of Homeland Security’s SenseNet program,” stated William J. Caragol, Chairman and CEO of PositiveID. “We believe our Firefly Dx system, coupled with ENSCO’s systems expertise, can provide an ideal solution for the biological detection capabilities that DHS is pursuing.”
ENSCO, Inc., and its wholly owned subsidiaries represent a $90 million technology enterprise, headquartered in the Washington, D.C., area. For more than 45 years, the ENSCO group of companies has been providing ingenious engineering, science and advanced technology solutions that guarantee mission success, safety and security to governments and private industries around the globe. ENSCO operates in the defense, transportation, aerospace and intelligence sectors. Field offices and subsidiaries, representatives and partnerships are located throughout the United States and around the world. www.ensco.com
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID’s future expectations, including, without limitation, the likelihood that PositiveID will offer its Firefly Dx system, which is a point-of-need system designed to deliver molecular diagnostic results using real-time PCR chemistry; the likelihood that Firefly would enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems, helping to save lives; the likelihood that ENSCO will be responsible for the systems integration and decision support; the likelihood that PositiveID’s Firefly Dx system, coupled with ENSCO’s systems expertise, can provide an ideal solution for the biological detection capabilities that DHS is pursuing; and all statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, PositiveID’s ability to target the bio-threat detection and rapid medical testing sectors, PositiveID’s ability to complete the development of the Firefly Dx system; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 11, 2014, and 10-Qs filed on August 14, 2014, May 20, 2014, and November 19, 2013, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Julie Hancock, Marketing Communications